

Esophageal  
CancerHead  
and Neck  
CancerTesticular  
Cancer

## MAY

Melanoma  
and Skin  
CancerBrain  
CancerBladder  
Cancer

## Inside this issue:

|  |   |
|--|---|
| OCISS Updates                              | 1 |
| New Cancer Publications                    | 2 |
| OCISS Data Use<br>by Researchers           | 3 |
| Cancer Registrar<br>Training Opportunities | 3 |
| NAACCR Webinar Summaries                   | 4 |
| Head and Neck                              | 4 |
| Data Items                                 | 4 |
| V23 Update Webinar                         | 5 |
| OCISS Staff Coding Tips                    | 5 |
| OCISS Contact Information                  | 6 |

# OCISS Newsletter

## Ohio Cancer Incidence Surveillance System



### OCISS Updates

#### National Cancer Registrars Week

National Cancer Registrars Week was April 3-7, 2023. This year's theme was *Harvesters of Data to Nurture Cancer Research*. Cancer registrars capture the data that supports advancements in cancer research, allows better monitoring and improvements in cancer treatment, and enables targeting cancer prevention and screening programs. There would not be cancer surveillance without cancer registrars, their extensive knowledge, and the quality of data they generate. Thank you for the important work that you do every day!

#### Cancer Reporting in 2023

At this time, OCISS cannot accept data for cases diagnosed in 2023 or NAACCR Version 23 (v23) format. OCISS will be upgrading Web Plus to v23 to accept these cases and files. The Centers for Disease Control and Prevention (CDC) indicated Web Plus v23 should be available this spring and OCISS plans to implement Web Plus v23 by July 2023. We will keep you posted about our timelines and progress. We appreciate your patience as we complete this software conversion.

For hospitals with their own registry software, OCISS will be able to accept v22 and v23 files when we update Web Plus to v23. If you update to v23 before OCISS does, and are no longer able to export v22 files, then you can put your reporting on hold until the OCISS conversion is complete. We understand that you may need to complete the v23 upgrade for other purposes, so please keep us posted on your v23 software conversion and notify OCISS of any delays in reporting. Please contact Kaitlin Kruger ([Kaitlin.Kruger@odh.ohio.gov](mailto:Kaitlin.Kruger@odh.ohio.gov)) with any questions that you may have.

## NAACCR v23 Reporting Changes

There are several changes in NAACCR v23 that will impact OCISS reporters. There will be an additional primary site surgery field introduced in v23 – Surgery Primary Site 2023. Only one Surgery Primary Site field will need to be completed depending on the year of diagnosis. The new surgery field will need to be completed for all cases diagnosed in 2023 and later. The old surgery field will be completed for cases diagnosed prior to 2023. Additionally, the date flag fields have been retired and will be removed from edits and the forms in Web Plus. OCISS requires date of diagnosis, date of birth, and date of last contact to be completed on all abstracts. This will be enforced with new state-specific edits in v23. We are asking everyone to please take special care in reporting treatment dates moving forward. Also, OCISS will continue to require the OH Tobacco History field in v23. OCISS will provide additional information when we begin collecting 2023 diagnoses. For more information on reporting changes in v23 and updated reporting manuals, please see [NAACCR's reference page](#). OCISS is also requiring date of first contact. Only the Date of Last and First Contact are state-specific. Standard edits will require Date of Diagnosis and Date of Birth. Finally, there will be a new site-specific data item (SSDI) collected by OCISS for appendix cases only, called "histologic subtype."

## NAACCR v23A Changes Spreadsheet

For hospital reporters with their own registry software who may have upgraded to v23 already, there are some

known issues with the v23 edits. These will be corrected in the "[NAACCR V23A changes spreadsheet](#)."

## OCISS Transitions

OCISS is pleased to welcome Emily Bunt as our new OCISS manager. Emily comes to us from the Comprehensive Cancer Program and the Breast and Cervical Cancer Project at ODH. As the researcher/evaluator for these programs, she used OCISS data for planning and evaluation as well as in the development of the state cancer plan. She is also a member of a team that writes reports on Ohio's cancer incidence, including the *Cancer Stats & Facts for Ohio* fact sheet series. Emily's contact information is listed on the last page of this newsletter. Welcome, Emily!

## Annual Report to the Nation

The national standard setters have released an update for the Annual Report to the Nation on the Status of Cancer. This report is an update of rates for new cases, deaths, and trends for the most common cancers in the United States through 2019. This is a joint effort between the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), The North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI). OCISS data is included in these analyses. You can access the report at either the [American Cancer Society](#) or [National Cancer Institute](#) websites.

---

## New Cancer Publications

The Ohio Department of Health (ODH) has recently posted new reports to the OCISS [Data and Statistics page](#).

**Ohio Annual Cancer Report 2023:** This new report provides a summary of cancer incidence and mortality data, stage at diagnosis, survival, and trends. It can be found on the ODH [Data and Statistics page](#), under Ohio Cancer Profiles.

**Obesity-Associated Cancers in Ohio 2023:** This report provides Ohio-specific data and information about the prevalence of obesity in Ohio and the cancers associated with overweight and obesity, including trends in cancer incidence and mortality. See: [Obesity-Associated Cancers in Ohio 2023 | Ohio Department of Health](#).

**Cancer Across the Lifespan in Ohio:** This new report provides information about cancer incidence and mortality rates in Ohio for five age groups across the lifespan: children 0-14 years old; adolescents and young adults, 15-39 years old; adults, 40-64 years old; adults, 65-84 years old; and adults, 85 years old and older. See: [Cancer Across the Lifespan in Ohio | Ohio Department of Health](#).

**Cancer Stats and Facts for Ohio Cancer Among Children Ages 0-14 Years Old:** This one-page fact sheet summarizes the findings in *Cancer Across the Lifespan in Ohio* for this age group. See: [Cancer Among Children Ages 0-14 Years Old | Ohio Department of Health](#).

**Prostate Cancer in Ohio 2023:** This report includes Ohio-specific information on prostate cancer incidence and mortality, trends, stage at diagnosis, survival, risk factors, signs and symptoms, screening, grade, and treatment. See: [Prostate Cancer in Ohio 2023 | Ohio Department of Health](#).

**Uterine Cancer in Ohio 2023:** This report includes Ohio-specific information on uterine (endometrial) cancer incidence and mortality, trends, stage at diagnosis, survival, histologic type, risk factors, signs and symptoms, and early detection. See: [Uterine Cancer in Ohio 2023 | Ohio Department of Health](#).

**Ohio Cancer Atlas 2023:** County-level maps of cancer incidence, mortality, risk factors, and social determinants of health showing geographic patterns of cancer rates and associated factors across the state. See: [Ohio Cancer Atlas 2023 | Ohio Department of Health](#).

---

## OCISS Data Use by Researchers

The ODH Institutional Review Board (IRB) is a group of individuals from various state agencies who review any research involving human subjects that uses any State of Ohio data. OCISS provides data for many on-going research projects that have ODH IRB approval. For more information, please see the ODH [IRB website](#). Since the last OCISS newsletter, there have been three new IRB-approved studies using OCISS data.

- **Study on the incidence of Cancer diagnosis and mortality among military aviators and aviation support personnel.** The Primary Investigator (PI) is Dr. Natalie Wells, MD, MPH, from The Defense Health Agency/Armed Forces Health Surveillance Division. This study focused on the incidence of cancer diagnosis and mortality among military aviators and aviation support personnel. The assumed primary exposures of concern for the study population include ionizing radiation associated with high altitude flight; nonionizing radiation associated with airborne, ground, and shipboard radars; and exposure to carcinogenic toxins or hazardous materials associated with flight operations from shipboard or land bases or facilities including fuels, fumes, and other liquids. This study is required by The National Defense Authorization Act FY 2021 Sec. 750.
- **Healthcare access and equity in patients and survivors of children, young adults, and non-elderly adults on Medicaid.** The Primary Investigator (PI) is Dr. Siran Koroukian, PhD, from Case Western Reserve University. This study is using OCISS data and Medicaid data, along with data from the Los Angeles Cancer Surveillance Program, to characterize the "cancer experience" of children, adolescents, young adults, and non-elderly adults on Medicaid, to look at racial-ethnic and socioeconomic disparities in outcomes.
- **Estimating the impact of community-targeted interventions to reduce barriers to screening in men with prostate cancer.** The Primary Investigator (PI) is Dr. Hari Iyer, ScD, MPH, from Rutgers Cancer Institute of New Jersey. This study is looking for barriers to men receiving prostate cancer screenings (PSA tests) and ways to reduce those barriers, specifically for men living in specific areas of Ohio.

---

## Cancer Registrar Training Opportunities

*Below are some important, upcoming conferences and training events in 2023:*

### **National Cancer Registrars Association (NCRA) Annual Educational Conference**

*Sailing Towards New Horizons*

May 7-10, 2023

San Diego, California

More information can be found on the [2023 NCRA Annual Conference](#) page.

### **North American Association of Central Cancer Registries (NAACCR) Annual Conference**

June 20-22, 2023

The Roosevelt New Orleans, Louisiana

See the [2023 NAACCR Annual Conference](#) page for more information.

### Ohio Cancer Registrars Association (OCRA) 53<sup>rd</sup> Annual Educational State Meeting

Sept. 21-22, 2023

North Canton, Ohio

More information can be found by visiting [OCRA's events page](#).

### American Health Information Management Association (AHIMA) Convention and Exhibit 2023

Oct. 8-11, 2023

Baltimore Convention Center, Baltimore, Maryland

See the [AHIMA education and events page](#) for more information.

---

## NAACCR Webinar Summaries

NAACCR hosts monthly webinars that provide three continuing education credits. OCISS makes these available **free** for cancer reporters via Web Plus and the Fundamental Learning Collaborative for the Cancer Surveillance Community (FLccSC) platform. For Web Plus access, contact Kaitlin Kruger ([Kaitlin.Kruger@odh.ohio.gov](mailto:Kaitlin.Kruger@odh.ohio.gov)) or 614-728-2304. To create a user account in FLccSC, visit the [FLccSC student page](#), click "New Users-Register here," and complete the registration form. Under "How do you categorize yourself?" please select "Ohio Student." For FLccSC questions please contact Jeremy Laws ([Jeremy.Laws@odh.ohio.gov](mailto:Jeremy.Laws@odh.ohio.gov) 614-644-9101).

The following are abstract highlights and tips from recent NAACCR webinars. **NOTE:** Some webinars cover topics in more depth than may be needed for all cancer reporters and may include data that are not collected by OCISS.

---

### Head and Neck (January 2023 Webinar)

*This webinar covered anatomy, solid tumor rules, staging and treatment of head and neck cancers.*

- The head and neck can be broken into regions, comprising of 79 sites, including Thyroid: C00.9-C14.8 and C30.0-C32.9.
- Refer to the [SEER Solid Tumor Rules](#) to determine number of primaries and histology.
- Registrars should first attempt to code to a specific primary site, and only use ill-defined/general head and neck primary sites as a last resort. For example, Tonsil C09.9 is located within the Oropharynx C10.9 and is a more specific primary site.

---

### Data Item Relationships (February 2023 Webinar)

This webinar highlighted specific data item codes, including staging, primary site, and histology. It demonstrated how the relationships between data items are used to create edits, perform quality control, conduct analysis, and perform visual review. It discussed how important data items are generated, such as: [Schema ID](#), [AJCC ID](#), [SSDI](#)s, grade, and surgery codes. Lastly, it highlighted the importance of correctly identifying primary site and histology. Refer to the [2023 Solid Tumor Rules](#) to determine the primary site and histology.

## V23 Update Webinar: ICD O, Solid Tumor Rules, SSDI

This free supplemental [NAACCR webinar](#) reviewed new terms, changes in behavior, and new histologies that are being implemented for diagnosis year 2023. New and updated SSDI's and changes to the Solid Tumor Rules Manual were also highlighted.

There are minor revisions for the existing [Solid Tumor Rules \(STR\)](#) modules:

- Breast.
- Head & Neck.
- Malignant and Non-malignant CNS.
- Nineteen new histology tables for most sites covered in "Other."

NAACCR V23 References:

- 2023 NAACCR Implementation Guidelines: <https://www.naaccr.org/implementation-guidelines/>.
- ICD-O-3.2 Coding Updates: Use of implementation guidelines is required for determining reportability: <http://www.naaccr.org/icdo3/>.
- SSDI and Grade Manual Version 3.0 Change Log: <https://apps.naaccr.org/ssdi/list/>.
- SEER Program Coding and Staging Manual 2023, Summary of Changes: <http://seer.cancer.gov/tools/codingmanuals/>.
- STORE 2023, Summary of Changes: <https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/ncdb-call-for-data/registry-manuals/>.
- Solid Tumor Rules, Revision History <https://seer.cancer.gov/tools/solidtumor/revisions.html>.
- The "CTR Guide to Coding Radiation Therapy Treatment" is now found in [STORE 2023](#), Appendix R.

---

## OCISS Staff Coding Tips

Tobacco Use/Smoking Fields:

OCISS will continue to collect tobacco history in our state specific field. "OH Tobacco History" should be reported for cases diagnosed in 2016 and later. Additionally, OCISS is requiring the new Smoking Status/Tobacco Use field be reported for cases diagnosed in 2022 and later. These fields should be in concert, as much as possible. Additionally, please **add** tobacco use information in the **PE text** field of abstracts to confirm the coding choices. See p. 80 of the [STORE manual](#) or the table below for additional guidance:

| If OH Tobacco History is...                               | Then Tobacco Smoking Status should be... |
|---|--|
| 0 - Never used  | 0 - Never Smoker                         |
| 1 - Cigarette smoker, current                             | 1 - Current some day smoker              |
| 2 - Cigar/pipe smoker, current                            | 1 - Current some day smoker              |
| 3 - Snuff/chew/smokeless, current                         | 9 - Unknown if ever smoked               |
| 4 - Comination use, current                               | 9 - Unknown if ever smoked               |
| 5 - Previous use  | 2 - Former smoker                        |
| 6 - E-cigarette, current                                  | 9 - Unknown if ever smoked               |
| 7 - Other tobacco use, current (waterpipes, dissolvables) | 9 - Unknown if ever smoked               |
| 9 - Unknown   | 9 - Unknown if ever smoked               |

**Skin, Melanoma In Situ cases:**

A true melanoma in situ (MIS) case cannot have lymphovascular invasion (LVI) present. The correct code for LVI for an in situ tumor is '0' (not present/not identified). From p. 146 of [STORE v23](#) and p. 137 of the [2023 SEER Coding and Staging Manual](#):



"Use code 0:

- When the pathology report indicates that there is no lymphovascular invasion.
- This includes cases of purely in situ carcinoma, which biologically have no access to lymphatic or vascular channels below the basement membrane.

### Social Security Number (SSN) Input Reminder:

- Enter the SSN number without dashes or a suffix.
- Always enter a patient's entire social security number, if available.
- If only the last four numbers are available, the number should always be *recorded with five preceding ones*. Example: 111114321.
- If no social security number is found in the patient record, the number should be entered as all nines. Example: 999999999.
- For more information please see ([NAACCR Data Dictionary, item 2320](#)).

Questions or suggestions for the OCISS Newsletter? Please contact Jeremy Laws ([Jeremy.Laws@odh.ohio.gov](mailto:Jeremy.Laws@odh.ohio.gov), 614-644-9101) or email the general OCISS inbox ([OCISS@odh.ohio.gov](mailto:OCISS@odh.ohio.gov)) with subject line "OCISS Newsletter."

## OCISS Contact Information

| OCISS Staff              | Contact for questions on:   | Contact Information  |
|--------------------------|---|--|
| Jamie Fike               | Lung, Heart, Thymus, Stomach, Esophagus   | <a href="mailto:Jamie.Fike@odh.ohio.gov">Jamie.Fike@odh.ohio.gov</a>                           |
| Rebecca Levings, RHIT    | Colorectal, Anus, Liver, Thyroid, and Pituitary Gland, Unknown Primary Site                             | <a href="mailto:Rebecca.Levings@odh.ohio.gov">Rebecca.Levings@odh.ohio.gov</a>                 |
| Bill Ruisinger, CTR      | Head & Neck, Bladder, Ureter, Renal Pelvis, Other Unspecified Urinary, Oral, Blood, Lymph Nodes, Spleen | <a href="mailto:William.Ruisinger@odh.ohio.gov">William.Ruisinger@odh.ohio.gov</a>             |
| Sheri Stuckey            | Breast, Gall Bladder, Biliary Tract   | <a href="mailto:Sheri.Stuckey@odh.ohio.gov">Sheri.Stuckey@odh.ohio.gov</a>                     |
| Cyndi Worden             | Pancreas, Penis, Female Genital Organs, Kidney  | <a href="mailto:Cynthia.Worden@odh.ohio.gov">Cynthia.Worden@odh.ohio.gov</a>                   |
| Angela Huff-Allen, CCS   | Prostate, Male Genital Organs   | <a href="mailto:Angela.Huff-Allen@odh.ohio.gov">Angela.Huff-Allen@odh.ohio.gov</a>             |
| Mahima Jain              | Skin, Tonsil  | <a href="mailto:Mahima.Jain@odh.ohio.gov">Mahima.Jain@odh.ohio.gov</a>                         |
| Cheryl Radin-Norman, CTR | Laryngeal, Bones, Soft Tissues, CNS, Bone Marrow, Peripheral Nerves                                     | <a href="mailto:Cheryl.L.Radin-Norman@odh.ohio.gov">Cheryl.L.Radin-Norman@odh.ohio.gov</a>     |
| Roberta Slocumb          | Data Requests   | <a href="mailto:Roberta.Slocumb@odh.ohio.gov">Roberta.Slocumb@odh.ohio.gov</a> or 614-995-5972 |
| Kaitlin Kruger           | Web Plus Access, Password Resets  | <a href="mailto:Kaitlin.Kruger@odh.ohio.gov">Kaitlin.Kruger@odh.ohio.gov</a> or 614-728-2304   |
| Jeremy Laws, CTR         | Cancer Reporting  | <a href="mailto:Jeremy.Laws@odh.ohio.gov">Jeremy.Laws@odh.ohio.gov</a> or 614-644-9101         |
| Emily Bunt               | General Registry Questions  | <a href="mailto:Emily.Bunt@odh.ohio.gov">Emily.Bunt@odh.ohio.gov</a> or 614-995-5433           |
| OCISS                    | General Information   | <a href="mailto:OCISS@odh.ohio.gov">OCISS@odh.ohio.gov</a> or 614-752-2689                     |